Genentech Bets $1.5B+ on Earendil’s Bispecifics With $55M Upfront
The one clean upfront among this week’s discovery deals, and Earendil keeps more of the early clinical risk than most.
NeuroPulse
DealPulse Signal
The Beats
Analysis
The Briefs
Genentech Bets $1.5B+ on Earendil’s Bispecifics With $55M Upfront
Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront
J&J Is Using Two Tecvayli Trials to Own Myeloma’s First Relapse Whether or Not Patients Had Darzalex
Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment
Roche Claims Best-in-Class Potential for Sefaxersen Without Disclosing How Much It Cut Proteinuria